Bellerophon to receive a license payment of $6 million, as well as royalties on net sales in Greater China
Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced that it has entered into a license agreement for the development and commercialization of INOpulse® with Baylor BioSciences, a life sciences company dedicated to the development and commercialization of innovative medical products for Greater China.
Under the terms of the license agreement, Bellerophon will receive a license payment of $6 million, payable within 90 days subject to certain closing conditions set forth in the agreement. Additionally, Bellerophon is entitled to royalties of 5% on net sales resulting from all of the licensed INOpulse indications within Greater China. Baylor BioSciences will receive exclusive rights to develop and commercialize INOpulse within Greater China for diseases associated with pulmonary hypertension, including the lead indication of fibrotic interstitial lung disease (fILD), as well as PH-Sarcoidosis and PH-COPD.
https://finance.yahoo.com/news/bellerophon-therapeutics-announces-license-agreement-133000392.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.